Last updated: September 25, 2026
Propoxyphene and acetaminophen has limited current pharmaceutical opportunity because propoxyphene was withdrawn from the U.S. market over cardiac safety concerns. The principal commercial issue is regulatory viability, not excipient differentiation. Historical products such as Darvocet-N and Darvon compound used immediate-release oral tablets containing propoxyphene napsylate and acetaminophen, but no active U.S. exclusivity protects the combination. A new product would face substantial safety, clinical, and market-access barriers.
What is the regulatory status of propoxyphene and acetaminophen?
Propoxyphene-containing products are no longer marketed in the United States. In November 2010, the FDA requested withdrawal of all propoxyphene products after new data showed a risk of serious and potentially fatal cardiac rhythm abnormalities, including QT prolongation, even at therapeutic doses. The manufacturer withdrew Darvon and Darvocet from the U.S. market shortly afterward.[1]
The combination historically used propoxyphene napsylate with acetaminophen. U.S. products included:
| Historical product |
Propoxyphene component |
Acetaminophen strength |
Dosage form |
U.S. status |
| Darvocet-N 50 |
Propoxyphene napsylate 50 mg |
325 mg |
Immediate-release tablet |
Withdrawn |
| Darvocet-N 100 |
Propoxyphene napsylate 100 mg |
650 mg |
Immediate-release tablet |
Withdrawn |
| Generic propoxyphene/APAP products |
Propoxyphene napsylate or hydrochloride |
Various |
Tablets and capsules |
Withdrawn |
The FDA stated that the risk could not be adequately managed through labeling changes or restricted prescribing.[1] That conclusion materially limits the commercial value of an excipient-led reformulation.
Is propoxyphene and acetaminophen FDA approved?
The combination was historically approved in the United States, but propoxyphene products are no longer legally marketed there. FDA withdrawal removed the commercial pathway for new generic or reformulated versions based on the old product profile.
An applicant seeking approval today would need to address the known cardiac toxicity of the active ingredient. A conventional abbreviated new drug application would not solve that problem because the principal barrier is product safety, not bioequivalence.
What excipient strategy was used in historical products?
Historical propoxyphene and acetaminophen tablets were immediate-release solid oral dosage forms. Their excipient strategy was conventional for compressed tablets:
| Excipient function |
Typical strategic role |
| Diluent or filler |
Provides tablet mass and supports compression |
| Binder |
Improves granule and tablet strength |
| Disintegrant |
Promotes breakup after oral administration |
| Lubricant |
Reduces sticking and ejection force |
| Glidant |
Improves powder flow |
| Film coating |
Controls appearance, handling, taste, and identification |
| Opacifier or colorant |
Supports product differentiation and light protection |
| Moisture-control excipients |
Improve stability where active ingredients or coating systems are moisture-sensitive |
The commercial objective was rapid, reproducible release of both active ingredients. A modified-release design would have been difficult to justify because the product was used as an analgesic and already carried opioid-related risks. Delayed or extended release could also create concerns about dose dumping, accumulation, and delayed toxicity.
What formulation risks affect propoxyphene and acetaminophen?
The active ingredients create different formulation and regulatory concerns.
Propoxyphene is a low-dose opioid with central nervous system effects and a narrow safety margin in overdose. Its metabolites and cardiac effects increase the consequences of dose variability and accidental overuse.
Acetaminophen has a well-established risk of dose-dependent hepatotoxicity. The fixed-dose combination creates a second safety constraint: patients may take additional acetaminophen-containing products without recognizing the cumulative daily dose.
A formulation program would therefore need to control:
- Content uniformity of the low-dose propoxyphene component.
- Dissolution consistency for both active ingredients.
- Tablet weight and blend segregation.
- Physical stability under heat and humidity.
- Packaging protection against medication errors.
- Clear strength differentiation between products.
- Risk of accidental duplicate acetaminophen exposure.
- Compatibility with tamper-evident and child-resistant packaging.
The excipient system cannot eliminate the underlying electrophysiologic or hepatic risks. It can improve manufacturing control and product usability, but it cannot create a meaningful safety defense against propoxyphene-induced arrhythmia.
What formulations could be protected by patents?
A new patentable formulation could theoretically claim a specific excipient combination, particle-size distribution, coating system, taste-masking approach, packaging configuration, or manufacturing process. The commercial value of such claims would be limited because patentability does not overcome the regulatory problem associated with propoxyphene.
Potential technical claim areas include:
- A composition with defined excipient ratios and dissolution limits.
- A low-segregation blend for uniform distribution of low-dose propoxyphene.
- A moisture-protective coating and packaging combination.
- A tamper-resistant immediate-release tablet.
- A formulation designed to reduce powder abuse or extraction.
- A capsule or multiparticulate system with controlled dose uniformity.
- A manufacturing process that reduces degradation or polymorphic conversion.
- A packaging and labeling system intended to reduce duplicate acetaminophen use.
These concepts would face obviousness challenges if based on standard tablet technology. A patent estate would need a measurable technical effect, such as a specific stability gain, dissolution profile, manufacturability improvement, or abuse-deterrent property.
Are there active patents protecting propoxyphene and acetaminophen?
The principal composition and product patents associated with historical propoxyphene products are decades old and would generally be expired. Any surviving patent would need to concern a later-developed formulation, manufacturing method, delivery system, or packaging technology rather than the basic combination.
The main commercial barriers are therefore:
- FDA safety policy.
- Product withdrawal history.
- Clinical development cost.
- Controlled-substance compliance.
- Product-liability exposure.
- Weak prescriber and payer demand.
- Availability of safer analgesic alternatives.
The old brand names, including Darvocet and Darvon, do not create current market exclusivity. Trademark rights and patent rights are separate, and brand recognition does not support a relaunch without regulatory approval.
What is the Orange Book status of propoxyphene and acetaminophen?
There is no meaningful current U.S. Orange Book opportunity for a propoxyphene and acetaminophen product. Historical listings may remain identifiable as discontinued products or reference products, but discontinuation does not provide a live market pathway for generic entry.
The FDA’s withdrawal action was based on safety rather than ordinary patent expiration. A prospective applicant would not gain commercial access simply by demonstrating that historical patents had expired.
There is also no relevant biologic or biosimilar pathway. Propoxyphene and acetaminophen is a small-molecule fixed-dose combination. Any new product would fall within the small-molecule drug framework, with the applicable route depending on whether the applicant pursued an abbreviated, hybrid, or full application.
When did propoxyphene lose exclusivity?
The core exclusivity for propoxyphene and acetaminophen expired long before the U.S. withdrawal. Generic versions were available before 2010. The sequence was:
| Period |
Event |
| 1950s-1960s |
Propoxyphene combination products introduced and commercialized |
| 1970s-1990s |
Core composition and product protections expired or approached expiration |
| Before 2010 |
Multiple generic propoxyphene/APAP products marketed |
| November 2010 |
FDA requested withdrawal of all U.S. propoxyphene products |
| 2010-2011 |
U.S. products withdrawn from distribution |
| Current |
No normal U.S. generic-entry market for the combination |
There is no commercially relevant “patent cliff” remaining for the old product. The relevant cliff was regulatory withdrawal.
Which companies are challenging or replacing propoxyphene products?
No significant current U.S. generic challenge is expected because the reference product was withdrawn and the active ingredient is associated with a recognized safety risk. Competitive pressure comes from replacement therapies rather than paragraph IV litigation.
The practical alternatives include:
- Acetaminophen alone.
- Nonsteroidal anti-inflammatory drugs where clinically appropriate.
- Tramadol and other prescription analgesics.
- Buprenorphine products.
- Hydrocodone or oxycodone combinations, subject to controlled-substance restrictions.
- Nonpharmacologic pain-management interventions.
The FDA’s withdrawal decision reduced the commercial incentive for generic manufacturers such as Teva, Mylan, Sandoz, Endo, and other historical suppliers to maintain or develop propoxyphene products.
Are there paragraph IV challenges for propoxyphene and acetaminophen?
There is no active commercial paragraph IV landscape of significance. Paragraph IV litigation typically supports generic entry against an actively marketed reference product with listed patents. Propoxyphene’s U.S. withdrawal eliminated that conventional framework.
A future applicant would likely face regulatory review centered on safety and clinical justification rather than a patent dispute over an active branded reference product.
What commercial opportunities remain for excipients?
The opportunity is stronger in adjacent technical markets than in a new propoxyphene prescription product.
Analytical and reference-material applications
Demand may exist for:
- Pharmaceutical reference standards.
- Impurity and degradation-product standards.
- Dissolution and content-uniformity testing.
- Stability-indicating analytical methods.
- Toxicology and forensic testing.
- Legacy-product quality investigations.
These are service and laboratory opportunities, not broad prescription-drug opportunities.
Reformulation and manufacturing services
Contract development and manufacturing organizations may support:
- Historical product testing.
- Method transfer.
- Forced-degradation studies.
- Extractables and leachables work.
- Packaging compatibility studies.
- Controlled-substance manufacturing compliance.
The market is likely specialized and volume-limited.
Non-propoxyphene analgesic platforms
Excipient suppliers have a stronger opportunity in safer analgesic products that use similar formulation capabilities. Relevant platforms include:
- Acetaminophen immediate-release tablets.
- Lower-dose combination analgesics.
- Abuse-deterrent opioid formulations.
- Orally disintegrating analgesic tablets.
- Taste-masked liquid formulations.
- Modified-release products with clinically justified pharmacokinetics.
- Unit-dose packaging designed to reduce medication errors.
These applications can use the same technical strengths required for propoxyphene/APAP, including blend uniformity, rapid dissolution, moisture control, and dose differentiation, without relying on a withdrawn active ingredient.
How strong is the patent estate for this product?
The patent estate is weak from a present-day commercial perspective.
| Patent-estate factor |
Assessment |
| Core composition patents |
Expired or commercially irrelevant |
| Formulation patents |
Historical and unlikely to block current development |
| Method-of-use patents |
Limited practical value after withdrawal |
| Manufacturing patents |
Potentially narrow and nonblocking |
| Orange Book exclusivity |
No meaningful active opportunity |
| Biosimilar protection |
Not applicable |
| Trademark protection |
Separate from regulatory and patent rights |
| Freedom-to-operate risk |
More likely from new formulation patents than old product patents |
| Regulatory risk |
Very high |
| Commercial attractiveness |
Low for a U.S. prescription relaunch |
A new excipient patent could create a private exclusion right, but it would not solve the central question of whether regulators would authorize renewed marketing.
What generic launch scenarios exist?
Three scenarios are possible in theory:
- U.S. relaunch through a full regulatory program. This would require a persuasive benefit-risk case despite the FDA’s prior withdrawal decision. Commercial prospects are poor.
- Non-U.S. marketing in a jurisdiction that permits the product. This would depend on local authorization, current safety policy, controlled-substance rules, and available demand. Regulatory precedent in several major markets is unfavorable.
- Technical commercialization without patient treatment use. Reference standards, analytical services, and historical-product support are the most realistic opportunities.
The first scenario carries the highest development and liability risk. The third has the lowest regulatory exposure but also a much smaller addressable market.
What patent litigation and settlement agreements affect the product?
No material current U.S. patent litigation or settlement landscape is associated with propoxyphene and acetaminophen. Historical disputes, if any, do not create a current commercial pathway because the underlying products were withdrawn.
Settlement agreements involving old generic entry would also have limited value today. A settlement cannot override a product withdrawal or establish a right to market a drug that no longer has an acceptable FDA benefit-risk profile.
How does propoxyphene and acetaminophen compare with safer analgesic products?
| Factor |
Propoxyphene/APAP |
Acetaminophen alone |
Modern opioid or nonopioid alternative |
| U.S. commercial status |
Withdrawn |
Widely marketed |
Varies by product |
| Cardiac risk |
Material propoxyphene concern |
Not characteristic at therapeutic use |
Product-specific |
| Hepatic risk |
Acetaminophen-related |
Acetaminophen-related |
Varies |
| Controlled-substance burden |
High |
None |
Often high for opioids |
| Patent opportunity |
Limited |
Formulation and delivery opportunities |
More active platform opportunities |
| Generic competition |
Historical only |
Strong |
Varies |
| Excipient differentiation |
Limited value |
Meaningful for delivery and adherence |
Meaningful for abuse deterrence and release control |
| Relaunch potential |
Poor |
Stronger |
Depends on clinical profile |
Key Takeaways
- Propoxyphene and acetaminophen has no attractive U.S. relaunch opportunity because propoxyphene was withdrawn over serious cardiac safety risks.
- The old combination had conventional immediate-release tablet excipient technology.
- Core composition and product patents are expired or commercially irrelevant.
- There is no meaningful current paragraph IV, Orange Book, biosimilar, or settlement landscape.
- New excipient patents could cover formulation or manufacturing improvements, but they would not resolve the FDA safety barrier.
- The strongest opportunities are analytical standards, legacy-product testing, contract services, and excipient platforms for safer analgesic products.
- Acetaminophen-only, nonopioid, and abuse-deterrent analgesic formulations offer a stronger commercial target than propoxyphene-containing products.
FAQs
Can a company market propoxyphene and acetaminophen outside the United States?
Only if the relevant national regulator authorizes the product and permits propoxyphene use. The product’s withdrawal history in major markets makes a new approval difficult.
Is propoxyphene and acetaminophen a controlled substance?
Propoxyphene was regulated as an opioid controlled substance in the United States before withdrawal. Any handling of remaining material or reference standards may require controlled-substance compliance.
Can excipients reduce propoxyphene cardiac toxicity?
No conventional excipient strategy has been established to neutralize propoxyphene’s electrophysiologic risk. Excipients can improve manufacturing consistency but do not remove the active ingredient’s intrinsic toxicity.
Does acetaminophen create a separate patent opportunity?
Yes. Acetaminophen products can support formulation patents covering rapid disintegration, taste masking, liquid delivery, modified release, packaging, and combination-product designs. The opportunity is stronger without propoxyphene.
Could an abuse-deterrent propoxyphene tablet be commercialized?
An abuse-deterrent design would not necessarily overcome the FDA’s concern about cardiac toxicity at therapeutic exposure. Abuse deterrence addresses misuse pathways, while the central withdrawal issue involved pharmacologic safety.
References
- U.S. Food and Drug Administration. (2010, November 19). FDA recommends withdrawal of propoxyphene from the U.S. market. https://www.fda.gov
- U.S. Food and Drug Administration. (2010). Drug safety communication: FDA recommends against the continued use of propoxyphene. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (2010). Darvocet-N 50 and Darvocet-N 100 prescribing information.
- European Medicines Agency. (2009). European Medicines Agency recommends withdrawal of dextropropoxyphene-containing medicines. https://www.ema.europa.eu
